| Objective: To evaluate the efficacy and tolerability of RTX in the control of bladder spasm and micturitional symptoms of overactive bladder (OAB) during the early stage after transurethral resection of the prostate (TURP)Methods: this was a randomized controlled trial. 45 patients who underwent TURPfor symptomatic benign prostatic hyperplasia included in the study. The mean age was 67.84 + 6.92 years (range 52 to 85 years). The mean course of the illness was 6.89 + 5.69 years (range 0.6 to 20 years) . 45 patients were divided into 3 groups randomly(n=15, in each group): A,B and C. 100ml of RTX at a concerntration of 10~-8mol/L was instilled into the bladder preoperatively for 30 minutes in group A; group C received normal saline (NS) only. Group B received Tolterodine (2mg twice daily) before TURP. It was observed to rate of cystospasm and the related complications.Results: RTX instillation had no vesical irritation and other adverse effects, and nolocal anesthesia was required. The symptoms of OAB were improved immediately in all the patients after 1 day of RTX intervention. The decreases in both diurnal and nocturnal frequencies were significant (P < 0. 001) according to voiding diaries at 1 week after treatment. The symptoms score, the number of bladder spasm episodes, duration of bladder spasm, the time of bladder perfusion clearance and indwelling catheter delivery in RTX group reduced significantly as compared with control group CConclusions: Preoperative therapeutic intravesical instillations of RTX is believed to be effective and well tolerated in the prevention and treatment of both detrusor instability and bladder spasm caused by urethra obstruction. It also improves postoperative function of patients' bladder by preventing postoperative overactive bladder and bladder spastic pain without side effects. It can be a promising therapeutic method for patients with overactive bladder.
|
PDF Full Text Request